Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNK01001 in Active Ankylosing Spondylitis (Phase 2)
CTR20213330Phase 2Completed
- Sponsor
- Lynk Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zemprocitinib in ankylosing spondylitis (AS), sponsored by Lynk Pharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
zemprocitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20213330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213330.